脂联素与肝源性糖尿病的相关研究(3)
![]() |
第1页 |
参见附件(2065KB,3页)。
[6] 贺军,张玉香,张金田,等.肝源性糖尿病86例临床分析.医学综述,1997,3(3):159.
[7] Deurenberg P,Weststrate JA,Seidell JC,et al.Body mass index as a measure of body fatness:age and sexspecific prediction formulas.Br J Nutr,1991,65:105-114.
[8] 李光伟,潘孝仁,Stephen L,等.检测人群胰岛素敏感性的一项指标.中华内科杂志,1993,32:656-660.
[9] 丁百静,王文峰,徐章,等.瘦素对肝源性糖尿病患者胰岛素抵抗的作用.中国医药,2007,2(3):157-158.
[10] Marra F,Aleffi S,Bertolani C,et al.Adipokines and liver fibrosis.Eur Rer Med pharmacol Sci,2005,9(5):279-284.
[11] 霍丽梅,宋光耀,叶蔚.脂联素与2型糖尿病发生发展的研究进展.临床荟萃,2005,20(1):54-55.
[12] 鲍中英,刘梅生,苑晓冬.肝源性糖尿病患者血清脂联素的变化.中华传染病杂志,2008,26(7):440-441.
[13] Tietge UJ,Boker KH,Manns MP,et al.Elevated circulatiog adiponectin levels in liver cjrrhosis are associated with reduced liver function and altered hepatic heoiodynamics.Am J Physiol Endocrinol Metab,2004,287(1):E82-89.
[14] Yoda-Murakami M,Janiguchi M,Takahashi K,et al.Change in expression of GBP28/adiponectin in carbon tetrachloride administrated mouse liver.Biochem Biophys Res Commun,2001,285(2):372-377.
[15] Hui JM,Hodge A,Farrell GC,et al.Beyond insulin resistance in NASH:FNF-afpha or adiponectin?Hepatology,2004,40(1):46-54.
[16] Berg,Yang WS,Lee WJ,et al.Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein adiponectin.J Clin Endocrinol Metab,2001,86(8):3814-3819.
您现在查看是摘要介绍页,详见PDF附件(2065KB,3页)。
闂傚嫭鍔掔花顒勫嫉瀹ュ懎顫ら柛锝冨妼鐢洭宕濆☉宕囩缂傚啯鍨归悵顖炴焾閵娿儱鐎诲ǎ鍥e墲娴煎懘宕i鍐繑闁绘牕宕缓鐐濮橆剚鍠呴柟瀛樼墬濠€浣圭▔閳ь剛鈧姘ㄨⅶ闁告帒妫涘▓鎴濃枖閵娿儱鏂€濞村吋鑹鹃幉鍐裁规担绛嬫綌闁靛棴鎷�
婵繐鎷� pdf闁稿繈鍔嶉弸锟� 闂傚洠鍋撻悷鏇嫹 5 缂佸鍨伴崹搴ㄦ晬閸繂甯抽悹鎰潐閺佺偤宕樺畝鈧▍銉ㄣ亹閺囩偞鍊�婵絽绻愰妵澶愬矗椤栨瑤绨板Λ鏉挎瑜帮拷10濞戞搩浜炶ⅶ闁告帪鎷�闁挎稑顦埀顒婃嫹
閺傚洨鐝烽悧鍫熸綀鐏炵偘绨崢鐔绘啿娴f粍娼堟禍鐚寸礉閼汇儲鍋嶇拋銈勮礋濮濄倖鏋冩稉宥呯杹鐞氼偅鏁硅ぐ鏇氱返婢堆冾啀閸忓秷鍨傞梼鍛邦嚢閿涘矁顕柇顔绘閹存牜鏁哥拠婵嬧偓姘辩叀閹存垳婊戦敍灞惧灉娴狀剚鏁归崚浼粹偓姘辩叀閸氬函绱濇导姘辩彌閸楀啿鐨㈤幃銊ф畱娴f粌鎼ф禒搴㈡拱缂冩垹鐝崚鐘绘珟閵嗭拷
瀵邦喕淇婇弬鍥╃彿
閸忚櫕鏁為惂鐐
鐠囧嫯顔戦崙鐘插綖
閹兼粎鍌ㄩ弴鏉戭樋
閹恒劌鐡ㄧ紒娆愭箙閸欙拷
閸旂姴鍙嗛弨鎯版
|